Subtle Medical's new software is now available
for clinical use in the US, further redefining the speed and
quality of accelerated MRI
MENLO PARK,
Calif., July 17, 2024 /PRNewswire/ -- Subtle
Medical, a leading healthcare technology company using AI to
improve medical imaging, announced FDA clearance of their new
software solution, SubtleSYNTH™, which uses deep learning (DL) to
generate synthetic STIR images (SynthSTIR's) from already-acquired
T1 and T2 weighted contrasts.
SubtleSYNTH is complementary to Subtle's
FDA-cleared SubtleMR™ software, which enables accelerated
image acquisition of up to 60% for MRI procedures on any vendor,
make, or model of scanner. SubtleSYNTH creates synthetic STIR
images with zero acquisition time that are interchangeable with
conventionally acquired STIR images. It was validated for use in
the spine using a demographically diverse study recently published
in AJNR.
Subtle Medical was recently awarded a
$2.3 million NIH SBIR grant in 2023
to continue the expansion of the SubtleSYNTH technology. The
company has plans to expand the technology to brain and MSK imaging
in future releases. By using more data to enable even better
quality and faster imaging, Subtle's suite of imaging solutions
will redefine what's possible for the speed and quality of MRI
imaging.
"As we continue to explore the evolving landscape
of AI-based diagnostic imaging, our focus remains on developing
innovative solutions that set us apart. SubtleSYNTH represents a
significant advancement by reducing acquisition time for a common
MRI sequence to zero, enhancing operational efficiency," said
Ajit Shankaranarayanan, Chief
Product Officer at Subtle Medical. "We believe this software will
offer substantial time savings for both new and existing scanners,
reduce the need for rescans due to motion artifacts, and ease the
workload on radiologists and technologists, ultimately improving
patient care."
"These innovations are poised to not only
redefine the landscape of diagnostic imaging, but also simplify the
ever increasing complexity of workflows faced by technologists and
radiologists alike," expressed Josh
Gurewitz, Chief Commercial Officer at Subtle Medical. "With
the attainment of FDA clearance, we mark a new era of MRI quality
and efficiency. We will eagerly begin to deploy this valuable
new tool to customers to help them realize maximum potential of
improved quality and care."
Meet with us at RSNA 2024, or to receive a demo
and explore the benefits of SubtleSYNTH at your institution,
contact our team today.
About Subtle Medical
Subtle Medical is a leading global provider of
AI-powered technology for faster, safer and smarter medical
imaging. It has been named a CB Insights GenAI 50 company and two
time CB Insights Top AI 100 and Digital Health 150 company.
The company's cutting-edge solutions optimize imaging workflows,
improving productivity and patient experience. By harnessing the
power of artificial intelligence, Subtle Medical aims to
revolutionize medical imaging and transform the future of
healthcare. For more information, please visit subtlemedical.com or
email sales@subtlemedical.com.
Media Contact:
Josh Gurewitz
Chief Commercial Officer
925-922-2615
Josh@SubtleMedical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/subtle-medical-receives-fda-clearance-for-industry-first-ai-powered-synthetic-imaging-software-subtlesynth-302198830.html
SOURCE Subtle Medical, Inc.